The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury

Abstract

Abstract-Data from the Women's Health Study show that serum levels of growth-differentiation factor-15 (GDF-15), a distant member of the transforming growth factor-␤ superfamily, are an independent risk indicator for adverse cardiovascular events. However, the cellular sources, upstream regulators, and functional effects of GDF-15 in the cardiovascular system have not been elucidated. We have identified GDF-15 by cDNA expression array analysis as a gene that is strongly upregulated by nitrosative stress in cultured cardiomyocytes isolated from 1-to 3-day-old rats. GDF-15 mRNA and pro-peptide expression levels were also induced in cardiomyocytes subjected to simulated ischemia/reperfusion (I/R) via NO-peroxynitrite-dependent signaling pathways. GDF-15 was actively secreted into the culture supernatant, suggesting that it might exert autocrine/paracrine effects during I/R. To explore the in vivo relevance of these findings, mice were subjected to transient or permanent coronary artery ligation. Myocardial GDF-15 mRNA and pro-peptide abundance rapidly increased in the area-at-risk after ischemic injury. Similarly, patients with an acute myocardial infarction had enhanced myocardial GDF-15 pro-peptide expression levels. As shown by immunohistochemistry, cardiomyocytes in the ischemic area contributed significantly to the induction of GDF-15 in the infarcted human heart. To delineate the function of GDF-15 during I/R, Gdf-15 gene-targeted mice were subjected to transient coronary artery ligation for 1 hour followed by reperfusion for 24 hours. Gdf-15-deficient mice developed greater infarct sizes and displayed more cardiomyocyte apoptosis in the infarct border zone after I/R compared with wild-type littermates, indicating that endogenous GDF-15 limits myocardial tissue damage in vivo. Moreover, treatment with recombinant GDF-15 protected cultured cardiomyocytes from apoptosis during simulated I/R as shown by histone ELISA, TUNEL/Hoechst staining, and annexin V/propidium iodide fluorescence-activated cell sorting (FACS) analysis. Mechanistically, the prosurvival effects of GDF-15 in cultured cardiomyocytes were abolished by phosphoinositide 3-OH kinase inhibitors and adenoviral expression of dominant-negative Akt1 (K179M mutation). In conclusion, our study identifies induction of GDF-15 in the heart as a novel defense mechanism that protects from I/R injury. Key Words: growth-differentiation factor-15 Ⅲ ischemia/reperfusion Ⅲ apoptosis Ⅲ PI3K Ⅲ Akt C oronary reperfusion is the primary therapeutic goal in patients with acute myocardial infarction (AMI). Although reperfusion is essential for myocardial salvage, it may at first exacerbate cellular damage sustained during the ischemic period, a phenomenon known as reperfusion injury. 1 There is growing evidence that the myocardium adapts to ischemia/reperfusion (I/R) by synthesizing and responding to a variety of stress-induced growth factors and cytokines, and that identification of these endogenous homeostatic mechanisms may open new avenues to limit I/R injury. 2,3 ...

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

“…Circulating osteoprotegerin has been reported to be associated with cardiovascular outcomes, including mortality, MI, and incident heart failure, in several ACS cohorts 16, 17, 18, 19. However, although most of these studies include natriuretic peptides,16, 17, 19 troponins,16, 17, 18 and CRP16, 17, 18 in their adjustment strategy, none include GDF‐15, which increases in response to myocardial stress associated with inflammation and tissue damage30 and is becoming a recognized biomarker in ACS 9, 10, 14. In this large study population, the association between high osteoprotegerin levels at admission and risk of the primary end point or cardiovascular death was markedly attenuated and no longer significant after addition of NT‐proBNP, hs‐TnT, and GDF‐15 to the model that included clinical variables and inflammatory biomarkers.…”

Fator de diferenciação de crescimento 15: um novo biomarcador em pacientes com disfunção diastólica?

“…Experimental studies have shown that GDF-15 expression significantly increases in the heart after various forms of stress, including pressure overload 22,23 . Animal studies have shown that GDF-15 promotes protective, antiapoptotic and antihypertrophic effects in the heart 23 .…”

Czynnik różnicowania wzrostu 15 jako biomarker w niewydolności serca

“…W warunkach fizjologicznych ekspresja GDF-15 występuje w łożysku, prostacie, nerkach i w jelicie grubym [10]. Wyraźne nasilenie ekspresji GDF-15 z udziałem czynnika transkrypcyjnego p53 obserwuje się w makrofagach, kardiomiocytach i komórkach śródbłonka -najczęściej wskutek ich uszkodzenia, niedokrwienia lub stymulacji przez prozapalne cytokiny i reaktywne rodniki tlenowe [11][12][13] (ryc. 1) [14,15].…”